SaaS Development Company in Cambridge

Whether the product is regulated is the fork in a Cambridge SaaS budget. A scoped Cambridge SaaS MVP over 10 to 14 weeks covers product strategy, design, a multi-tenant build on Next.js and Node or Python, Stripe or GoCardless billing in GBP, UK data residency on AWS eu-west-2 (London), and an ICO Data Protection Impact Assessment; a production SaaS platform over 16 to 24 weeks adds role-based access, audit logging, SSO, and a public API. Software-as-a-medical-device builds with MHRA documentation, DCB 0129 and DCB 0160 clinical safety cases, ISO 13485 alignment, and NHS Digital DTAC compliance add scope for the regulated-quality work. Cambridge rates sit above Bristol and Manchester due to the deep-tech talent premium but below London. Fixed-fee proposals, not open time-and-materials. The Chandigarh hub keeps total cost competitive with onshore-only Cambridge firms while staying inside the GMT/BST working day.

Yes. The Cambridge Biomedical Campus (AstraZeneca's worldwide R&D HQ at the Discovery Centre, plus the MRC Laboratory of Molecular Biology, Addenbrooke's Hospital, and the Cambridge Centre for AI in Medicine) and the Babraham Research Campus produce constant demand for biotech and pharma SaaS. We integrate with ELN/LIMS platforms (Benchling, Dotmatics Signals Notebook, LabArchives, IDBS E-WorkBook), connect to regulated content systems on Veeva Vault patterns, deliver under MHRA expectations and the HRA Research Ethics Committee process, satisfy HTA licensing for human-tissue work, ARSAC for radiopharmaceutical pipelines, and ATMP regulations for advanced therapies. Quality-management alignment is ISO 13485 with documented design controls under IEC 62304 for software-as-a-medical-device, and the ISO 27001 plus Cyber Essentials Plus posture AstraZeneca-grade vendor governance demands.

For software that meets the definition of a medical device under the UK MDR 2002 (as amended), we deliver against MHRA expectations: a documented intended-purpose statement, classification under the UK MDR rules (Class I, IIa, IIb, or III), design controls under IEC 62304, risk management under ISO 14971, usability engineering under IEC 62366, and a quality management system aligned with ISO 13485. For NHS deployment we deliver a DCB 0129 clinical safety case (manufacturer's clinical risk-management documentation) and a DCB 0160 deployment safety case where the platform is deployed inside an NHS Trust. The NHS Digital Technology Assessment Criteria (DTAC) evidence pack covers clinical safety, data protection, technical security, interoperability, and usability and accessibility. We work alongside your regulatory consultant and clinical safety officer; we do not provide medical-device regulatory advice ourselves.

Yes. Cambridge biotech SaaS routinely integrates with Benchling (the dominant cloud ELN/LIMS for early-stage and scale-up biotech), Dotmatics Signals Notebook and Geneious Biologics (broadly used at AstraZeneca-grade pharma), LabArchives (popular with academic spinouts from the University of Cambridge), and IDBS E-WorkBook (large-pharma scale). For regulated content we integrate Veeva Vault patterns. For clinical-trial supporting tooling we connect to Medidata Rave, Castor EDC, and REDCap. For laboratory automation we integrate Tecan and Hamilton API surfaces. Every integration ships with documented authentication (OAuth 2.0 or mutual TLS), an audit trail suitable for FDA 21 CFR Part 11 and EU Annex 11 review where the platform sits in a GxP context, and a data-flow diagram for the qualified person's release decision.

Every Cambridge SaaS engagement opens with an ICO-aligned Data Protection Impact Assessment scoped to the lawful basis (typically Article 6(1)(f) legitimate interest for B2B, Article 6(1)(b) contract for B2C, plus Article 9(2) special-category processing for any health data with the relevant condition under Schedule 1 of the Data Protection Act 2018). For research processing we document the Article 6(1)(e) public-task basis and Article 9(2)(j) scientific-research condition where the HRA Research Ethics Committee approval supports it. International transfers use the UK International Data Transfer Agreement, the UK addendum to the EU Standard Contractual Clauses, or rely on the UK-EU adequacy decision for EEA processors. Production data sits inside AWS eu-west-2 (London) with eu-west-1 (Ireland) for DR, and subject-access, rectification, and erasure workflows are built into the admin console.

Where public or partner APIs exist, yes. ARM's developer ecosystem (Mbed, Keil, Arm Development Studio, Arm Virtual Hardware) exposes integration points for licensing, telemetry, and developer-tooling SaaS. We have built developer-platform integrations using the ARM Allstar and partner-portal patterns. For EDA we work with Cadence and Synopsys APIs where exposed, plus SiliconCompiler and OpenROAD for open-source flows. For semiconductor supply-chain SaaS we integrate with the Open Semiconductor Industry Standards (OSIS) data formats. Where the enterprise has no public API we scope a secure file-exchange pattern (SFTP with PGP, or a controlled file-share). For IP-licensing SaaS we have shipped against the contractual and audit patterns ARM and Imagination Technologies expect of partner-facing tooling.

Chandigarh runs IST (UTC+5:30), which is four-and-a-half hours ahead of Cambridge in BST and five-and-a-half hours ahead in GMT. In practice, a Cambridge 09:30 BST stand-up lands as a 14:00 IST late-afternoon meeting in Chandigarh, giving us a four-to-five-hour overlap window where Cambridge product, clinical, and regulatory leads coordinate live with the offshore engineering team. Code, tickets, design reviews, and clinical-safety updates handed off at 17:00 BST get picked up by Chandigarh and shipped back before Cambridge logs on at 08:30 BST the next morning. For AstraZeneca-grade vendor governance, the fixed-fee proposal makes that cadence contractual rather than a best-effort claim, and the Edmonton hub covers North American business hours when a Cambridge client has US subsidiaries or FDA-facing work that needs Eastern Time coordination.

A focused Cambridge SaaS MVP typically reaches paying customers in 12 to 16 weeks, assuming a scoped feature set and a standard UK GDPR posture without medical-device classification. Week 1 to 2 is paid discovery (product strategy, regulatory and integration audit, fixed-fee proposal). Week 3 to 6 is design, infrastructure (AWS eu-west-2 setup, CI/CD, observability), and the spine of the multi-tenant model. Week 7 to 12 is feature delivery in two-week sprints. Week 13 to 14 is hardening (pen test, ICO DPIA, WCAG 2.2 AA accessibility audit, performance pass). Week 15 to 16 is closed beta, paid beta, and general availability. Software-as-a-medical-device builds add 12 to 24 weeks for the design-control documentation, IEC 62304 software-development lifecycle artefacts, ISO 14971 risk-management file, DCB 0129 clinical safety case, and the NHS DTAC evidence pack.